S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NYSE:QGEN

Qiagen - QGEN Stock Forecast, Price & News

$50.46
+0.92 (+1.86%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$49.82
▼
$50.49
50-Day Range
$41.93
▼
$50.46
52-Week Range
$40.38
▼
$56.18
Volume
595,533 shs
Average Volume
1.06 million shs
Market Capitalization
$11.46 billion
P/E Ratio
25.10
Dividend Yield
N/A
Price Target
$56.53

Qiagen MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
12.0% Upside
$56.53 Price Target
Short Interest
Bearish
2.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.44mentions of Qiagen in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-9.48%
From $2.32 to $2.10 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

872nd out of 1,047 stocks

Biological Products, Except Diagnostic Industry

148th out of 173 stocks

See Top Rated MarketRank™ Stocks Here
QGEN stock logo

About Qiagen (NYSE:QGEN) Stock

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Stock News Headlines

December 2, 2022 | americanbankingnews.com
Financial Review: Qiagen (NYSE:QGEN) vs. Black Diamond Therapeutics (NASDAQ:BDTX)
November 26, 2022 | americanbankingnews.com
Brokerages Set Qiagen (NYSE:QGEN) Price Target at $54.65
November 25, 2022 | finance.yahoo.com
QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification
November 23, 2022 | finance.yahoo.com
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
November 21, 2022 | finance.yahoo.com
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
November 19, 2022 | finance.yahoo.com
Is Qiagen N.V.'s (NYSE:QGEN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
November 10, 2022 | finance.yahoo.com
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
November 2, 2022 | finance.yahoo.com
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity
October 31, 2022 | finance.yahoo.com
Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline
October 18, 2022 | finance.yahoo.com
Qiagen N.V. (NYSE:QGEN) is largely controlled by institutional shareholders who own 79% of the company
October 12, 2022 | seekingalpha.com
Will Bio-Rad & Qiagen Merge? I Can't See Any Logic To This Deal (NYSE:BIO) - Seeking Alpha
October 11, 2022 | investors.com
BIO Stock Extends Two-Day Dive On Rumored $10 Billion Qiagen Tie-Up - Investor's Business Daily
October 11, 2022 | finance.yahoo.com
Bio-Rad Laboratories, Qiagen Mull Merger Of Equals - Yahoo Finance
October 11, 2022 | wsj.com
Bio-Rad Laboratories in Talks to Combine With Qiagen - WSJ - The Wall Street Journal
October 11, 2022 | benzinga.com
Qiagen shares are trading higher following reports suggesting Bio-Rad Laboratories is in talks to combine with the company. - Qiagen (NYSE:QGEN) - Benzinga
October 11, 2022 | marketwatch.com
Bio-Rad Shares Fall After Report of Qiagen Talks - MarketWatch
October 10, 2022 | marketwatch.com
The Wall Street Journal: Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market
October 10, 2022 | streetinsider.com
Bio-Rad Labs (BIO) in Talks to Combine with Qiagen (QGEN) - DJ - StreetInsider.com
October 10, 2022 | seekingalpha.com
Qiagen stock down after BHF downgrades rating to Neutral - Seeking Alpha
October 10, 2022 | seekingalpha.com
Bio-Rad Laboratories in discussions with Qiagen to merge - WSJ - Seeking Alpha
October 10, 2022 | reuters.com
Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ - Reuters
October 10, 2022 | finance.yahoo.com
Insights on the Gene Expression Analysis Global Market to 2027 - Increasing Adoption of Targeted Molecular Therapeutics is Driving Growth - Yahoo Finance
October 5, 2022 | marketwatch.com
Laboratory Corp. of America Holdings stock falls Wednesday, underperforms market - MarketWatch
October 5, 2022 | marketwatch.com
Quest Diagnostics Inc. stock falls Wednesday, underperforms market - MarketWatch
October 5, 2022 | finance.yahoo.com
Demand for Global Nucleic Acid Isolation And Purification Market Size to Surpass USD 8260.30 Million by 2028, Exhibit a CAGR of 11.10% | Nucleic Acid Isolation And Purification Industry Trends, Share, Value, Analysis & Forecast Report by Fa - Yahoo Finance
See More Headlines
Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Company Calendar

Last Earnings
11/07/2022
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/14/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:QGEN
CUSIP
N/A
CIK
1015820
Web
www.qiagen.com
Phone
(177) 355-6600
Fax
31-77-355-6658
Employees
6,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$56.53
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$54.60
Forecasted Upside/Downside
+12.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.01
Trailing P/E Ratio
25.10
Forward P/E Ratio
21.75
P/E Growth
1.42
Net Income
$512.60 million
Net Margins
20.83%
Pretax Margin
25.70%
Return on Equity
18.43%
Return on Assets
9.54%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
1.84
Quick Ratio
1.62

Sales & Book Value

Annual Sales
$2.25 billion
Price / Sales
5.09
Cash Flow
$3.85 per share
Price / Cash Flow
13.11
Book Value
$14.65 per share
Price / Book
3.44

Miscellaneous

Outstanding Shares
227,070,000
Free Float
206,637,000
Market Cap
$11.46 billion
Optionable
Optionable
Beta
0.42

Key Executives

  • Mr. Thierry Bernard (Age 57)
    CEO, MD & Member of Management Board
    Comp: $2.02M
  • Dr. Roland Sackers (Age 53)
    CFO, MD & Member of Management Board
    Comp: $1.18M
  • Mr. Antonio Santos
    Sr. VP & Head of Global Operations
  • Mr. John Gilardi
    VP of Corp. Communications & Investor Relations
  • Ms. Stephany Foster
    Sr. VP & Head of HR
  • Dr. Thomas Schweins
    Sr. VP of Life Science Bus. Area
  • Dr. Thomas Theuringer
    Sr. Director & Head of External Communications
  • Mr. Jean-Pascal Viola
    Sr. VP & Head of Molecular Diagnostics Bus. Area
  • Dr. Jonathan G. Sheldon Ph.D. (Age 50)
    Sr. VP of Qiagen Digital Insights Bus. Area
  • Mr. Thomas Neidert
    VP of Global Treasury

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













QGEN Stock - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" QGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares.
View QGEN analyst ratings or view top-rated stocks.

What is Qiagen's stock price forecast for 2023?

6 brokerages have issued 12-month price objectives for Qiagen's stock. Their QGEN share price forecasts range from $54.60 to $60.00. On average, they anticipate the company's stock price to reach $56.53 in the next twelve months. This suggests a possible upside of 12.0% from the stock's current price.
View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts.

How have QGEN shares performed in 2022?

Qiagen's stock was trading at $55.58 on January 1st, 2022. Since then, QGEN stock has decreased by 9.2% and is now trading at $50.46.
View the best growth stocks for 2022 here.

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our QGEN earnings forecast.

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) released its quarterly earnings data on Monday, November, 7th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.45 by $0.08. The firm earned $499.63 million during the quarter, compared to the consensus estimate of $479.99 million. Qiagen had a net margin of 20.83% and a trailing twelve-month return on equity of 18.43%.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY 2022 earnings guidance on Monday, November, 21st. The company provided earnings per share (EPS) guidance of $2.40-$2.40 for the period, compared to the consensus EPS estimate of $2.21. The company issued revenue guidance of $2.25 billion-$2.25 billion, compared to the consensus revenue estimate of $2.13 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (9.02%), Vanguard Group Inc. (3.64%), BlackRock Inc. (3.24%), Pendal Group Ltd (2.32%), Marshall Wace LLP (1.04%) and State Street Corp (0.99%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $50.46.

How much money does Qiagen make?

Qiagen (NYSE:QGEN) has a market capitalization of $11.46 billion and generates $2.25 billion in revenue each year. The company earns $512.60 million in net income (profit) each year or $2.01 on an earnings per share basis.

How many employees does Qiagen have?

The company employs 6,000 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.

This page (NYSE:QGEN) was last updated on 12/2/2022 by MarketBeat.com Staff